CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
November 19, 2024
Pipeline
PharmaTher Announces Update on FDA New Drug Application for Ketamine
November 13, 2024
Pipeline
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
October 23, 2024
Pipeline
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
September 4, 2024
Pipeline
PharmaTher Announces Update on FDA New Drug Application for Ketamine
August 21, 2024
Pipeline
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 19, 2024
Pipeline
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
May 15, 2024
Pipeline
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 10, 2024
Pipeline
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 1, 2024
Pipeline
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
April 18, 2024
Pipeline
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
Pipeline
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 21, 2024
Pipeline
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of  Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 12, 2024
Pipeline
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
January 10, 2024
Pipeline
PharmaTher Provides Update for Expected FDA Approval of Ketamine
September 27, 2023
Pipeline
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketamine
September 6, 2023
Pipeline
PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketamine to the FDA
July 18, 2023
Pipeline
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
June 27, 2023
Pipeline
PharmaTher Initiates Filing of Abbreviated New Drug Application for Racemic Ketamine to the FDA
June 20, 2023
Platform & partnering
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of Racemic Ketamine in the U.S.
June 12, 2023
Corporate
PharmaTher Holdings Provides Corporate Update

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.